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Summary
Mutations in BRCA1 and BRCA2 genes are associated with the family predisposition 
to breast and ovarian cancer. The main purpose of genetic testing is an early detection of 
the predisposition,  because even early detection increases the effectiveness of treatment. 
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INTRODUCTION
Breast cancer is a leading cancer in female population worlwide. Epide-
miological data indicate 5-10 % of all breast and /or ovarian cancer cases are 
hereditary, and germline mutations in BRCA genes account for the majority 
of hereditary breast nad ovarian cancers [1]. By today, those two genes Breast 
Cancer Gene 1 (BRCA1) and Breast Cancer Gene 2 (BRCA2) are only known 
breast cancer predisposing genes, whose mutations can be first sign of fami-
lial setting, before cancer occurs. Those genes are tumor suppressors, invol-
ved in DNA repair processes, and are the major breast and ovarian cancer 
susceptibility genes.
The penetrance of deleterious BRCA mutations has been variably estima-
ted; a recent combined analysis of different reports [2] estimates the average 
cumulative risk (by the age of 70) in BRCA1 mutation cariers to be about  70 
% for breast cancer and 40 % for ovarian cancer, whereas the corresponding 
risk for BRCA2 are 45 % and 11 %. So, person with inherited mutation in 
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BRCA1 and BRCA2 genes have 45-85% probability of developing breast can-
cer, and 11-62% probability of developing ovarian cancer by age 70, compa-
ring to general population risk of 10%.
In familial setting, breast cancer occurs at young age and risk of bilateral 
breast and ovarian cancer is increased. Age of onset in subsequent genera-
tions of BRCA mutations carrying families is lower by 7,9 years [3].  Also, 
carriers of BRCA1 and BRCA2 mutations are at increased risk for other can-
cers: uterine, cervical, prostate, pancreatic, male breast, bile duct, stomac can-
cer and melanoma [4]. Breast cancer can occur in men as well, but the risk is 
100 times lower than in women.
In general population the overall prevalence of BRCA1 and BRCA2 mu-
tation carriers is estimated to be from 1 in 400 to1 in 800, the quite variable 
ratio among etnic groups and by geographic region.
Figure 1. Shematic presentation of the location of BRCA 1 gene mapped on chromosome 17 
and BRCA 2 gene on chromosome 13. There are listed also few data about size of the gene, 
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Most reported disease-associated alleles of BRCA1 and BRCA2 genes (Fi-
gure 1) have been attributed to frameshifts, nonsense or missense mutations, 
large rearrangements and splice alterations. They usually lead to truncated 
BRCA1 or BRCA2 protein or affect critical aminoacids  for its structure or 
function. However, a large number of sequence variants, particularly mi-
ssense variants, routinely encountered in clinical and research laboratories, 
cannot be readily distinguished  as either disease-causing (deleterious) mu-
tations or  benign polymorphisms (clinically not significant) and thus are 
classified as variants of unknown clinical significance.
To date, more than 3600 BRCA1 and BRCA2 variants have been reported 
in locus-specific databases like Breast Cancer Infromation Core (BIC) - http://
research.nhgri.nih.gov/bic/, than  Universal Mutation Database (UMD) - 
http://www.umd.be/BRCA1/ and  http://www.umd.be/BRCA2/, Leiden Open 
Variation Database - http://chromium.liacs.nl/LOVD2/cancer/home.php and 
kConFab - http://www.kconfab.org/Progress/Mutations.aspx.
Considering these numbers, genetic testing represents invaluable step 
forward in defynig these malignant disease. The testing is especially impor-
tant in predicting the risk of developing ovarian cancer, as this kind of can-
cer is difficult to detect until late, when the chances of cure are less efficient.
Unfortunately, every year in Croatia 2500 women develop breast cancer 
and 450 develop ovarian cancer, and more than 900 die of breast cancer and 
almost 400 deaths of ovarian cancer. According to statistical estimates based 
on 4,3 million Croatian population, at least two hundred breast cancers have 
familial predisposition, and those estimates follow general worldwide stati-
stics (data from Central Bureau of Statistics of Republic of Croatia and Croa-
tian National Institute of Public Health, 2006). No data on BRCA variants in 
affected population of Croatia have been gathered so far.
EXPERIENCE WITH GENETIC TESTING IN CROATIA
In Croatia few years ago conditions were appropriate for providing gene-
tic testing of inherited predisposition for breast and ovarian cancer . It was 
organized in Laboratory for Hereditary Cancer at Rudjer Boskovic Institute 
thanking to funds of Terry Fox donation and support by Croatian League 
against Cancer and Europa Donna Croatia. 
The screening was performed by high-resolution melting approach, di-
rect sequencing and semi-quantitative multiplex PCR method and provides 
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a comprehensive analysis on the type and distribution of BRCA1 and BRCA2 
mutations and allelic variants [5].
The test entails very complex molecular-genetic methods that have been 
used in most developed countries for decades. The Laboratory is a member 
of EMQN (European Molecular Genetics Quality Network), international 
organization focused on standardizing protocols for molecular genetics di-
agnostics and on quality assurance of its members. Therefore, the methods 
used are at the European level of quality. 
The main purpose of this testing was early detection of predisposition, 
because it lowers the cost of treatment as well as declines the need for long 
hospitalizations, chemotherapy, radiation and multiple surgeries. Even early 
detection increases the effectiveness of treatment. Targeted and preventive 
therapy, as well as the lifestyle changes can significantly decrease the mor-
tality.
CANDIDATES FOR TESTING
Each candidate has to undergo genetic counseling before and after te-
sting. The test is mainly for breast and ovarian cancer prone family mem-
bers and is not informative for sporadic cases of breast and ovarian cancer. 
BRCA1 and BRCA2 mutations are inheritable with the same probability from 
either parent.
Potential candidates for BRCA1 and BRCA2 mutation testing are:
- persons with two or more relatives with breast cancer 
- persons with early (before age of 50) breast cancer in the family
- persons with breast cancer in the family in more than one generation
- persons with bilateral breast cancer in the family
- persons with multiple ovarian cancer in the family
- persons with early (before age of 40) bilateral ovarian cancer
- persons with one or more relatives with BRCA1 and/or BRCA2 gene 
mutation in the family.
FIRST STUDY IN CROATIA
The results of BRCA1 and BRCA2 analysis in a group of 168 candidates 
from Croatia were selected for increased risk of breast and ovarian cancer on 
the basis of their personal or family history of the diseases. Candidates were 
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volunteers from several national associations and support groups for breast 
cancer patients, selected according to the set criteria.
In this study, 168 women from 147 families with positive family or per-
sonal history of breast and ovarian cancer were screened for mutations in 
BRCA1 and BRCA2 genes. All candidates gave their informed consent to per-
form DNA analysis on their blood samples before the samples were taken. 
The study was conducted according to the Declaration of Helsinki Principles.
The candidates were recruited from mostly all locations in Croatia (Ka-
štel Novi, Rijeka, Ploče, Šibenik, Osijek, Zagreb, Dubrovnik, Zadar, Čakovec, 
Karlobag, Gospić) and were classified into nine categories according to fa-
mily or personal history of disease. Table 1. shows the specific characteristics 
of the candidates according to the inclusion criteria.
Table 1. Inclusion criteria for the candidates included in this study (from 6).
Group Inclusion criteria Cases (%)
A affected individual with breast or ovarian cancer before 35 years of age 9 (5.3)
B affected individual with breast cancer before the age of 35 with at least 
one case of breast or ovarian cancer in the family
4 (2.4)
C affected individual with breast or ovarian cancer between the age of 35 
and 55 with at least one case of breast cancer in the family
14 (8.3)
D affected individual with breast or ovarian cancer between the age of 35 
and 55 with at least one case of breast and at least one case of ovarian 
cancer in the family
7 (4.2)
E unaffected individual with at least two cases of breast cancer in the family 65 (38.7)
F unaffected individual with at least one case of breast cancer in the family 
before 50 years of age
39 (23.2)
G unaffected individual with at least one case of breast and at least one case 
of ovarian cancer in the family
18 (10.7)
H unaffected individual with at least one ovarian cancer  in the family 8 (4.8)
I unaffected individual with at least one case of breast cancer and male 
breast cancer in the family
4 (2.4)
Total 168 (100)
Candidates in group A are considered early onset breast cancer patients, 
as the usual cut off for early onset is 35 years of age. 
From the 168 candidates which participated in this study, 32 (19%, age 
range 25-58, median 41) were affected with breast cancer, 2 (1.2%, ages 31 and 
53) with ovarian cancer, and one with both breast and ovarian cancer (0.6%, 
ovarian cancer in 51 and breast cancer in 54). The remaining candidates were 
unaffected (133) but with positive family history (groups E-I). 
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Mutations in BRCA1 and BRCA2 genes detected
Figure 2.  BRCA1 gene shematic presentation with marked type and position of detected 
mutations.
Figure 3.  BRCA2 gene shematic presentation with marked type and position of detected 
mutations.
Al together (in 10 %) genetic testing identified 14 pathogenic mutations 
in17 candidates, 9 in BRCA1 and 5 in BRCA2 (Figures 1 and 2).  Of those, 11 
have been previously described and 3 were novel [6]. 
Nine pathogenic mutations in BRCA1 and five in BRCA2 were detected 
[6]. Croatia shares most of the mutations with Slovenia and Germany . No 
founder mutations were detected in Croatia, although one is a candidate. 
Further analyses on a larger number of samples is necessary. 
The benefit of this testing is clear, since mutations were detected in young 
unaffected women who will be closely monitored. 
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Sažetak
Molekularna dijagnostika nasljednog raka dojke
Mutacije u genima BRCA1 i BRCA2 povezuju se sa nasljeđenom sklonošću za na-
stanak raka dojke i jajnika. Svrha genetičkog testiranja je utvrditi dovoljno rano postoji 
li predispozicija, čime bi se dovoljno rano mogle poduzeti učinkovite mjere prevencije.
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